{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-030075","form_type":"8-K","ticker":"AYTU","cik":"0001385818","company_name":"AYTU BIOPHARMA, INC","filed_at":"2024-09-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.862295+00:00","generated_at":"2026-05-31T01:30:10.328454+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aytu BioPharma FY2024 revenue $81M, adjusted EBITDA $9.2M; ADHD net revenue +23%","bullets":["FY2024 consolidated net revenue $81.0M (down 25% YoY); net loss $15.8M ($2.86/share)","Adjusted EBITDA improved to $9.2M from $3.5M ( +162%); Rx Business EBITDA $10.8M","ADHD Portfolio net revenue +23% to $57.8M; Pediatric unit shipments up 115% since July 1","Consumer Health Segment divested in July 2024; company expects Rx Segment revenue and EBITDA growth in FY2025","Cash balance $20.0M; refinanced term loan; $3.5M from warrant exercises"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-030075","json":"https://secwatch.observer/filing/0001437749-24-030075.json","markdown":"https://secwatch.observer/filing/0001437749-24-030075.md","text":"https://secwatch.observer/filing/0001437749-24-030075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/0001437749-24-030075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1385818/000143774924030075/aytu20240610_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T01:30:10.328454+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}